Soft-Tissue Augmentation During Implant Placement in the Aesthetic Zone: Clinical, Radiographic, Histological and Patient-Reported Outcomes From a Randomised Controlled Trial Using Connective Tissue Graft and a Volume-Stable Collagen Matrix.

J Clin PeriodontolJul 28, 2026 (epub)
Clinical ResearchPlastic Surgery

Louiza Papantonatou, Leonidas Batas, Antigoni Delantoni et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effects of soft-tissue augmentation (STA) during implant placement in the aesthetic zone using connective tissue graft (CTG) or volume-stable collagen matrix (VCMX) in 25 patients. Both VCMX and SCTG significantly increased soft-tissue thickness (STT) compared to the control group (p < 0.001), with VCMX showing numerically greater gains.

Key findings

  • Both VCMX and SCTG significantly increased STT compared to control (p < 0.001).
  • Numerically greater STT gains were observed in the VCMX group.
  • BBT decreased significantly over time in all groups, with no significant differences between treatments.
  • CTG was associated with slightly higher morbidity compared to VCMX.

Why it matters

Understanding the effectiveness of different soft-tissue augmentation techniques is crucial for optimizing aesthetic outcomes in implant dentistry. This study provides evidence that both methods can enhance soft-tissue thickness, which may improve aesthetic results.

Source

PubMed · PMID 42521470

Published in J Clin Periodontol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.